Lv1
30 积分 2022-05-06 加入
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
2天前
已完结
Surgical robotics: Impact of motion scaling on task performance
21天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
沿肝中静脉解剖性半肝切除治疗区域型肝胆管结石34例
5个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
10个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
10个月前
已完结
177P Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310)
10个月前
已关闭
皖公网安备34019202002308
